SG169332A1 - Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases - Google Patents

Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases

Info

Publication number
SG169332A1
SG169332A1 SG201100390-2A SG2011003902A SG169332A1 SG 169332 A1 SG169332 A1 SG 169332A1 SG 2011003902 A SG2011003902 A SG 2011003902A SG 169332 A1 SG169332 A1 SG 169332A1
Authority
SG
Singapore
Prior art keywords
rosacea
retinoids
treatment
skin diseases
inflammatory skin
Prior art date
Application number
SG201100390-2A
Other languages
English (en)
Inventor
Thomas Zollner
Soenke Johannsen
Original Assignee
Intendis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intendis Gmbh filed Critical Intendis Gmbh
Publication of SG169332A1 publication Critical patent/SG169332A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG201100390-2A 2006-01-23 2007-01-23 Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases SG169332A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76095206P 2006-01-23 2006-01-23
DE102006004804A DE102006004804A1 (de) 2006-01-23 2006-01-23 Verwendung von Alkandicarbonsäuren und Retinoiden zur Behandlung entzündlicher Hauterkrankungen

Publications (1)

Publication Number Publication Date
SG169332A1 true SG169332A1 (en) 2011-03-30

Family

ID=38219816

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201100390-2A SG169332A1 (en) 2006-01-23 2007-01-23 Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases

Country Status (14)

Country Link
US (1) US20110160306A1 (fr)
EP (2) EP2316444A3 (fr)
JP (1) JP2009523750A (fr)
KR (1) KR20080086515A (fr)
CN (1) CN101370489A (fr)
AU (1) AU2007207027A1 (fr)
BR (1) BRPI0707180A2 (fr)
CA (1) CA2633774A1 (fr)
DE (1) DE102006004804A1 (fr)
IL (1) IL191908A0 (fr)
NO (1) NO20083637L (fr)
RU (1) RU2008134316A (fr)
SG (1) SG169332A1 (fr)
WO (1) WO2007082780A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201930A1 (fr) 2008-12-23 2010-06-30 Intendis GmbH Composition d'hydrogel pour le traitement des troubles dermatologiques
US20100273756A1 (en) * 2009-04-27 2010-10-28 Reza Babapour Adjunctive formulation and methods for palliation of fine wrinkles, mottled hyperpigmentation, tactile roughness of facial skin and related disorders
DE102010021671A1 (de) 2010-05-27 2011-12-01 Intendis Gmbh Azelainsäurehaltige Formulierung mit Pigmentzusatz
TW201311295A (zh) * 2011-06-03 2013-03-16 Allergan Inc 對皮脂腺之類視色素化合物之目標遞送
RU2500395C1 (ru) * 2012-12-07 2013-12-10 Закрытое акционерное общество Фармацевтическое научно-производственное предприятие "Ретиноиды" Мазевая композиция для местного применения с противоугревой фармакологической активностью
WO2017019951A2 (fr) 2015-07-30 2017-02-02 Curology, Inc. Compositions et procédés de traitement de l'acné et du photovieillissement
WO2017192928A1 (fr) 2016-05-06 2017-11-09 Albany Medical College Traitement de la rosacée avec des inhibiteurs de la voie p38 et erk kinase
US12150949B2 (en) 2018-07-30 2024-11-26 Curology, Inc. Compositions and methods of treating acne and photoaging
KR102081029B1 (ko) * 2019-08-12 2020-02-25 연세대학교 산학협력단 수베르산 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물
WO2021029659A1 (fr) * 2019-08-12 2021-02-18 연세대학교 산학협력단 Composition destinée à prévenir ou traiter des maladies allergiques ou une dermatite atopique comprenant de l'éthylvanilline, de l'acide subérique, du thiazole ou un sel de ceux-ci en tant que principe actif
CN114518416B (zh) * 2020-11-20 2024-05-24 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物
CN116710087A (zh) * 2020-11-23 2023-09-05 美国商业眼科医疗器械公司 用于治疗眼部病症的制剂和方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1075741B (it) 1977-04-19 1985-04-22 Porro Marcella Composizione per il trattamento di dermatosi iperpigmentarie
US4661519A (en) * 1983-04-12 1987-04-28 Pola Chemical Industries Inc. Method for dermatological application
US5326790A (en) * 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
DE3811081A1 (de) 1988-03-30 1989-10-12 Schering Ag Verwendung von topisch applizierbaren praeparaten zur behandlung der altershaut
IT1242478B (it) 1990-02-20 1994-03-17 Schering Spa Composizioni farmaceutiche ad attivita' depigmentante e contro il danneggiamento cutaneo fotoindotto.
FR2714602B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition antiacnéique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
JP2001509137A (ja) * 1996-11-12 2001-07-10 タマーキン ファーマシューティカル イノベイション リミテッド 皮膚疾患の治療方法
CN1091371C (zh) 1996-12-26 2002-09-25 苏洪国 换肤粉刺霜
SE9801647D0 (sv) * 1998-05-12 1998-05-12 Interhealth Ab Therapeutic composition
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6358541B1 (en) * 2000-05-03 2002-03-19 David S. Goodman Topical preparation for the treatment of hair loss
GB0128052D0 (en) * 2001-11-22 2002-01-16 Drug Discovery Lab As Compounds
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US7328924B2 (en) * 2003-12-12 2008-02-12 Phd, Inc. Adjustable tip assembly
US20050169948A1 (en) * 2004-01-29 2005-08-04 Bernstein Joel E. Method and compositions for treatment of acne vulgaris and acne rosacea
ITBS20040068A1 (it) * 2004-05-24 2004-08-24 Gen Topics Srl Composizione cosmetica e/o farmaceutica per il trattamento della rosacea

Also Published As

Publication number Publication date
JP2009523750A (ja) 2009-06-25
BRPI0707180A2 (pt) 2011-04-26
CA2633774A1 (fr) 2007-07-26
AU2007207027A1 (en) 2007-07-26
RU2008134316A (ru) 2010-02-27
CN101370489A (zh) 2009-02-18
KR20080086515A (ko) 2008-09-25
EP2316444A3 (fr) 2011-06-01
WO2007082780A1 (fr) 2007-07-26
NO20083637L (no) 2008-10-07
DE102006004804A1 (de) 2007-07-26
US20110160306A1 (en) 2011-06-30
IL191908A0 (en) 2009-08-03
EP2316444A2 (fr) 2011-05-04
EP1976499A1 (fr) 2008-10-08

Similar Documents

Publication Publication Date Title
IL191908A0 (en) Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases
WO2008106102A9 (fr) Inhibiteurs de rtp801 et leur utilisation dans le traitement de diverses maladies
SI2056807T1 (sl) Zdravljenje vnetnih bolezni
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
PH12013500876A1 (en) Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
PT3279663T (pt) Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
EP2021016A4 (fr) Antagonistes de cxcl13 et leur utilisation pour le traitement de maladies inflammatoires
EP2051732A4 (fr) Diagnostic et traitement de troubles du métabolisme et procédés à cet effet
EP2702142A4 (fr) Procédé d'utilisation d'agents biologiques comprenant des formes vivantes ou dormantes de bactéries et autres organismes dans le traitement d'infections, d'une inflammation et autres maladies de l'intestin grêle distal et du gros intestin
ZA201106056B (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
GB0701970D0 (en) Treatment of protein aggregation diseases
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
IL185775A0 (en) Pomegranate-derived products for the treatment of skin sores and lesions
ZA201105320B (en) Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
GB0608647D0 (en) Methods of diagnosis and treatment
ZA200807874B (en) Preventative treatment and remission of allergic diseases
BRPI0922482A2 (pt) derivados de 1-amino-alquilciclohexano para o tratamento de doencas inflamatórias da pele
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases